As the global cell and gene therapy (CGT) industry evolves, companies across the sector are reassessing how to build sustainable growth in an increasingly regionalized and innovation-driven market. For TFBS Bioscience, this has meant focusing on long-term partnerships, regional manufacturing and testing capabilities, and strategic expansion across the Asia-Pacific.
Headquartered in Taiwan, TFBS Bioscience operates in one of the most dynamic areas of biotechnology, providing integrated development, testing, and manufacturing services for advanced therapies. As global demand for CGT solutions to grow, the company has adopted an Asia-first growth strategy designed to strengthen collaboration and support the region’s expanding biotechnology ecosystem, which differs significantly from traditional biologics in both technology complexity and diversity.
“Japan became a natural starting point for our international expansion,” says Tatung Yuan, Ph.D., Chairman and Chief Executive Officer.
“Geographic proximity to Taiwan, existing professional relationships, and strong industry potential created an attractive foundation. Japan is making significant investments in the future of cell and gene therapy through policies designed to strengthen domestic manufacturing capabilities, research infrastructure, and innovation ecosystems.”
Recognizing these trends early, TFBS Bioscience established a strategy focused on supporting Japan’s rapidly developing CGT market through the integration of technical expertise spanning preclinical testing to manufacturing, based on an one-stop-shop model. The company believes that building trust through consistent project execution and localized partnerships is essential for sustainable growth in the advanced therapy sector.
“As demand for advanced therapies accelerates across the Asia-Pacific, we will continue to strengthen our position as a trusted partner helping shape the future of biotechnology innovation alongside local partners.”
Tatung Yuan, Ph.D., Chairman and Chief Executive Officer, TFBS Bioscience
In recent years, TFBS Bioscience has expanded its regional engagement through collaborations with research institutions, biotechnology companies, and industry partners across Japan, includingthe CGT alliance between Teijin Regenet and TFBS Bioscience. The company views these partnerships as an important foundation for future growth and cross-border innovation within the Asia-Pacific biotechnology landscape.
Beyond Japan, TFBS Bioscience has also identified South Korea and Australia as promising markets where specialized expertise and strategic partnerships can create strong competitive advantages.
“Our company follows a disciplined approach, focusing on establishing local relationships before entering new territories,” says Yuan.
“This strategy reflects our broader philosophy at TFBS Bioscience: growth should be built on long-term value rather than short-term opportunities. As demand for advanced therapies accelerates across the Asia-Pacific, we will continue to strengthen our position as a trusted partner helping shape the future of biotechnology innovation alongside local partners.”
